Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/2024-519071-25-00
2024-519071-25-00RecruitingPhase 1

An Open-label, Multicenter, Phase 1a/1b Study to Evaluate the Safety and Anti-tumor Activity of TT125-802 in Combination With Adagrasib or Osimertinib in Patients with Advanced NSCLC

TOLREMO therapeutics AG3 sites in 1 country90 target enrollmentStarted: June 27, 2025Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Recruiting
Enrollment
90
Locations
3
Study OverviewEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Eligibility Criteria

Ages
18 years to 65+ years (18-64 Years, 65+ Years)
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Pharmaceutical company
Responsible Party
Principal Investigator
Principal Investigator

Chief Executive Officer

Scientific

TOLREMO therapeutics AG

Study Sites (3)

Loading locations...

Similar Trials

Recruiting
Phase 1
Tuvusertib (M1774) in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322)on-Squamous Non-Small Cell Lung Cancer
CTIS2022-502010-85-00Merck Healthcare KGaA198
Recruiting
Phase 1
M1774 in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322)on-Squamous Non-Small Cell Lung Cancer
JPRN-jRCT2031230332Ishii Kyoko25
Active, not recruiting
Phase 1
Clinical trial conducted in two parts: the first (phase I) to find out the safe dose of BIBF 1120 in the treatment of patients with liver cancer and the second part (phase II) to compare this dose of BIBF 1120 with Sorafenib in the treatment of hepatocellular carcinoma (liver cancer)Histologically or cytologically confirmed hepatocellular carcinoma not amenable to local therapy with adequate renal, hematological and liver paramenters with Child-Pugh score 5-6, in 1st line systemic therapy.
EUCTR2009-011925-14-ATBoehringer Ingelheim RCV GmbH & Co. KG132
Active, not recruiting
Phase 1
Clinical trial conducted in two parts: the first (phase I) to find out the safe dose of BIBF 1120 in the treatment of patients with liver cancer and the second part (phase II) to compare this dose of BIBF 1120 with Sorafenib in the treatment of hepatocellular carcinoma (liver cancer)Histologically or cytologically confirmed hepatocellular carcinoma not amenable to local therapy with adequate renal, hematological and liver paramenters with Child-Pugh score 5-6, in 1st line systemic therapy.
EUCTR2009-011925-14-DEBoehringer Ingelheim Pharma GmbH & Co. KG132
Active, not recruiting
Phase 1
Clinical trial conducted in two parts: the first (phase I) to find out the safe dose of BIBF 1120 in the treatment of patients with liver cancer and the second part (phase II) to compare this dose of BIBF 1120 with Sorafenib in the treatment of hepatocellular carcinoma (liver cancer)Histologically or cytologically confirmed hepatocellular carcinoma not amenable to local therapy with adequate renal, hematological and liver paramenters with Child-Pugh score 5-6, in 1st line systemic therapy.
EUCTR2009-011925-14-NLBoehringer Ingelheim bv132